{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T01:05:40Z","timestamp":1784250340583,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Talent research project of Suzhou Gusu Health Talents Program","award":["GSWS202037"],"award-info":[{"award-number":["GSWS202037"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82102826"],"award-info":[{"award-number":["82102826"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100019643","name":"State Key Laboratory of Radiation Medicine and Protection","doi-asserted-by":"crossref","award":["GZK12024032"],"award-info":[{"award-number":["GZK12024032"]}],"id":[{"id":"10.13039\/501100019643","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02178-4","type":"journal-article","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T05:53:21Z","timestamp":1779602001000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PSMC2 promotes hepatocellular carcinoma progression through interaction with EGFR"],"prefix":"10.1007","volume":"26","author":[{"given":"Yecheng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunxue","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengfei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,24]]},"reference":[{"issue":"1","key":"2178_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2178_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-024-02075-w","volume":"10","author":"J Zheng","year":"2025","unstructured":"Zheng J, Wang S, Xia L, et al. Hepatocellular carcinoma: signaling pathways and therapeutic advances. Signal Transduct Target Ther. 2025;10(1):35. https:\/\/doi.org\/10.1038\/s41392-024-02075-w.","journal-title":"Signal Transduct Target Ther"},{"issue":"Suppl","key":"2178_CR3","doi-asserted-by":"publisher","first-page":"S228","DOI":"10.3350\/cmh.2024.0824","volume":"31","author":"SY Hwang","year":"2025","unstructured":"Hwang SY, Danpanichkul P, Agopian V, et al. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment. Clin Mol Hepatol. 2025;31(Suppl):S228\u201354. https:\/\/doi.org\/10.3350\/cmh.2024.0824.","journal-title":"Clin Mol Hepatol"},{"key":"2178_CR4","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1146\/annurev-biochem-062917-011931","volume":"87","author":"JAM Bard","year":"2018","unstructured":"Bard JAM, Goodall EA, Greene ER, Jonsson E, Dong KC, Martin A. Structure and Function of the 26S Proteasome. Annu Rev Biochem. 2018;87:697\u2013724. https:\/\/doi.org\/10.1146\/annurev-biochem-062917-011931.","journal-title":"Annu Rev Biochem"},{"issue":"4","key":"2178_CR5","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.cell.2011.02.005","volume":"144","author":"DM Smith","year":"2011","unstructured":"Smith DM, Fraga H, Reis C, Kafri G, Goldberg AL. ATP binds to proteasomal ATPases in pairs with distinct functional effects, implying an ordered reaction cycle. Cell. 2011;144(4):526\u201338. https:\/\/doi.org\/10.1016\/j.cell.2011.02.005.","journal-title":"Cell"},{"issue":"3","key":"2178_CR6","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1159\/000502224","volume":"64","author":"J He","year":"2019","unstructured":"He J, Xing J, Yang X, et al. Silencing of Proteasome 26S Subunit ATPase 2 Regulates Colorectal Cancer Cell Proliferation, Apoptosis, and Migration. Chemotherapy. 2019;64(3):146\u201354. https:\/\/doi.org\/10.1159\/000502224.","journal-title":"Chemotherapy"},{"issue":"8","key":"2178_CR7","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41419-021-03981-5","volume":"12","author":"D Zhu","year":"2021","unstructured":"Zhu D, Huang J, Liu N, Li W, Yan L. PSMC2\/CCND1 axis promotes development of ovarian cancer through regulating cell growth, apoptosis and migration. Cell Death Dis. 2021;12(8):730. https:\/\/doi.org\/10.1038\/s41419-021-03981-5.","journal-title":"Cell Death Dis"},{"issue":"5","key":"2178_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41389-021-00330-1","volume":"10","author":"D Zhu","year":"2021","unstructured":"Zhu D, Gu X, Lin Z, Yu D, Wang J. High expression of PSMC2 promotes gallbladder cancer through regulation of GNG4 and predicts poor prognosis. Oncogenesis. 2021;10(5):43. https:\/\/doi.org\/10.1038\/s41389-021-00330-1.","journal-title":"Oncogenesis"},{"key":"2178_CR9","doi-asserted-by":"publisher","first-page":"607021","DOI":"10.3389\/fonc.2021.607021","volume":"11","author":"Y Liu","year":"2021","unstructured":"Liu Y, Chen H, Li X, et al. PSMC2 Regulates Cell Cycle Progression Through the p21\/Cyclin D1 Pathway and Predicts a Poor Prognosis in Human Hepatocellular Carcinoma. Front Oncol. 2021;11:607021. https:\/\/doi.org\/10.3389\/fonc.2021.607021.","journal-title":"Front Oncol"},{"issue":"1","key":"2178_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41420-021-00585-y","volume":"7","author":"X Duan","year":"2021","unstructured":"Duan X, Li H, Wang M, et al. PSMC2\/ITGA6 axis plays critical role in the development and progression of hepatocellular carcinoma. Cell Death Discov. 2021;7(1):217. https:\/\/doi.org\/10.1038\/s41420-021-00585-y.","journal-title":"Cell Death Discov"},{"key":"2178_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semcancer.2022.04.002","volume":"85","author":"E Levantini","year":"2022","unstructured":"Levantini E, Maroni G, Del Re M, Tenen DG. EGFR signaling pathway as therapeutic target in human cancers. Semin Cancer Biol. 2022;85:253\u201375. https:\/\/doi.org\/10.1016\/j.semcancer.2022.04.002.","journal-title":"Semin Cancer Biol"},{"key":"2178_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1146\/annurev-med-051718-013524","volume":"71","author":"CY Yang","year":"2020","unstructured":"Yang CY, Yang JC, Yang PC. Precision Management of Advanced Non-Small Cell Lung Cancer. Annu Rev Med. 2020;71:117\u201336. https:\/\/doi.org\/10.1146\/annurev-med-051718-013524.","journal-title":"Annu Rev Med"},{"issue":"6","key":"2178_CR13","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.2013.53.7746","volume":"33","author":"AX Zhu","year":"2015","unstructured":"Zhu AX, Rosmorduc O, Evans TR, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33(6):559\u201366. https:\/\/doi.org\/10.1200\/JCO.2013.53.7746.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2178_CR14","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1054\/bjoc.2000.1580","volume":"84","author":"Y Ito","year":"2001","unstructured":"Ito Y, Takeda T, Sakon M, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer. 2001;84(10):1377\u201383. https:\/\/doi.org\/10.1054\/bjoc.2000.1580.","journal-title":"Br J Cancer"},{"issue":"40","key":"2178_CR15","doi-asserted-by":"publisher","first-page":"e2405459","DOI":"10.1002\/advs.202405459","volume":"11","author":"P Cao","year":"2024","unstructured":"Cao P, Chen H, Zhang Y, et al. Genomic Amplification of TBC1D31 Promotes Hepatocellular Carcinoma Through Reducing the Rab22A-Mediated Endolysosomal Trafficking and Degradation of EGFR. Adv Sci (Weinh). 2024;11(40):e2405459. https:\/\/doi.org\/10.1002\/advs.202405459.","journal-title":"Adv Sci (Weinh)"},{"issue":"11","key":"2178_CR16","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41419-023-06293-y","volume":"14","author":"DS Wen","year":"2023","unstructured":"Wen DS, Huang LC, Bu XY, et al. DNA methylation-activated full-length EMX1 facilitates metastasis through EMX1-EGFR-ERK axis in hepatocellular carcinoma. Cell Death Dis. 2023;14(11):769. https:\/\/doi.org\/10.1038\/s41419-023-06293-y.","journal-title":"Cell Death Dis"},{"issue":"10","key":"2178_CR17","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1038\/s41388-017-0068-0","volume":"37","author":"L Sun","year":"2018","unstructured":"Sun L, Yu S, Xu H, et al. FHL2 interacts with EGFR to promote glioblastoma growth. Oncogene. 2018;37(10):1386\u201398. https:\/\/doi.org\/10.1038\/s41388-017-0068-0.","journal-title":"Oncogene"},{"issue":"7","key":"2178_CR18","doi-asserted-by":"publisher","first-page":"e3000410","DOI":"10.1371\/journal.pbio.3000410","volume":"18","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 2020;18(7):e3000410. https:\/\/doi.org\/10.1371\/journal.pbio.3000410.","journal-title":"PLoS Biol"},{"issue":"1","key":"2178_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12935-021-01934-8","volume":"21","author":"Q Chen","year":"2021","unstructured":"Chen Q, Fu L, Hu J, Guo G, Xie A. Silencing of PSMC2 inhibits development and metastasis of prostate cancer through regulating proliferation, apoptosis and migration. Cancer Cell Int. 2021;21(1):235. https:\/\/doi.org\/10.1186\/s12935-021-01934-8.","journal-title":"Cancer Cell Int"},{"issue":"5","key":"2178_CR20","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/15384101.2021.2021722","volume":"21","author":"Z Wang","year":"2022","unstructured":"Wang Z, Xiong H, Zuo Y, Hu S, Zhu C, Min A. PSMC2 knockdown inhibits the progression of oral squamous cell carcinoma by promoting apoptosis via PI3K\/Akt pathway. Cell Cycle. 2022;21(5):477\u201388. https:\/\/doi.org\/10.1080\/15384101.2021.2021722.","journal-title":"Cell Cycle"},{"issue":"21\u201322","key":"2178_CR21","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1080\/15384101.2023.2293590","volume":"22","author":"J Su","year":"2023","unstructured":"Su J, Hu S, Ding S, Feng K. PSMC2 knockdown exerts an anti-tumor role in nasopharyngeal carcinoma through regulating AKT signaling pathway. Cell Cycle. 2023;22(21\u201322):2381\u201391. https:\/\/doi.org\/10.1080\/15384101.2023.2293590.","journal-title":"Cell Cycle"},{"issue":"3","key":"2178_CR22","doi-asserted-by":"publisher","first-page":"152802","DOI":"10.1016\/j.imbio.2024.152802","volume":"229","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhang S, Zhao Z, et al. PSMC2 promotes glioma progression by regulating immune microenvironment and PI3K\/AKT\/mTOR pathway. Immunobiology. 2024;229(3):152802. https:\/\/doi.org\/10.1016\/j.imbio.2024.152802.","journal-title":"Immunobiology"},{"issue":"4","key":"2178_CR23","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.cell.2012.07.023","volume":"150","author":"D Nijhawan","year":"2012","unstructured":"Nijhawan D, Zack TI, Ren Y, et al. Cancer vulnerabilities unveiled by genomic loss. Cell. 2012;150(4):842\u201354. https:\/\/doi.org\/10.1016\/j.cell.2012.07.023.","journal-title":"Cell"},{"issue":"7","key":"2178_CR24","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/s41419-021-03960-w","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhu M, Li J, et al. Overexpression of PSMC2 promotes the tumorigenesis and development of human breast cancer via regulating plasminogen activator urokinase (PLAU). Cell Death Dis. 2021;12(7):690. https:\/\/doi.org\/10.1038\/s41419-021-03960-w.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2178_CR25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41420-021-00727-2","volume":"7","author":"Y Yang","year":"2021","unstructured":"Yang Y, Qi F, Wei C, et al. PSMC2 knockdown suppressed tumor progression of skin cutaneous melanoma. Cell Death Discov. 2021;7(1):323. https:\/\/doi.org\/10.1038\/s41420-021-00727-2.","journal-title":"Cell Death Discov"},{"issue":"1","key":"2178_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41389-022-00386-7","volume":"11","author":"T Liu","year":"2022","unstructured":"Liu T, Zhang J, Chen H, et al. PSMC2 promotes the progression of gastric cancer via induction of RPS15A\/mTOR pathway. Oncogenesis. 2022;11(1):12. https:\/\/doi.org\/10.1038\/s41389-022-00386-7.","journal-title":"Oncogenesis"},{"issue":"24","key":"2178_CR27","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.1158\/0008-5472.CAN-24-1846","volume":"84","author":"E Sementino","year":"2024","unstructured":"Sementino E, Hassan D, Bellacosa A, Testa JR. AKT and the Hallmarks of Cancer. Cancer Res. 2024;84(24):4126\u201339. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-1846.","journal-title":"Cancer Res"},{"issue":"1","key":"2178_CR28","doi-asserted-by":"publisher","first-page":"e1563","DOI":"10.1002\/ctm2.1563","volume":"14","author":"C Su","year":"2024","unstructured":"Su C, Zhang H, Mo J, Liao Z, Zhang B, Zhu P. SP1-activated USP27X-AS1 promotes hepatocellular carcinoma progression via USP7-mediated AKT stabilisation. Clin Transl Med. 2024;14(1):e1563. https:\/\/doi.org\/10.1002\/ctm2.1563.","journal-title":"Clin Transl Med"},{"issue":"10","key":"2178_CR29","doi-asserted-by":"publisher","first-page":"114812","DOI":"10.1016\/j.celrep.2024.114812","volume":"43","author":"H Zhang","year":"2024","unstructured":"Zhang H, Wang Z, Zhang J, et al. A MYC-STAMBPL1-TOE1 positive feedback loop mediates EGFR stability in hepatocellular carcinoma. Cell Rep. 2024;43(10):114812. https:\/\/doi.org\/10.1016\/j.celrep.2024.114812.","journal-title":"Cell Rep"},{"issue":"7869","key":"2178_CR30","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","volume":"595","author":"H Jin","year":"2021","unstructured":"Jin H, Shi Y, Lv Y, et al. EGFR activation limits the response of liver cancer to lenvatinib. Nature. 2021;595(7869):730\u20134. https:\/\/doi.org\/10.1038\/s41586-021-03741-7.","journal-title":"Nature"},{"issue":"1","key":"2178_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s13046-024-03062-3","volume":"43","author":"Y Su","year":"2024","unstructured":"Su Y, Meng L, Ge C, et al. Correction: PSMD9 promotes the malignant progression of hepatocellular carcinoma by interacting with c-Cbl to activate EGFR signaling and recycling. J Exp Clin Cancer Res. 2024;43(1):287. https:\/\/doi.org\/10.1186\/s13046-024-03062-3.","journal-title":"J Exp Clin Cancer Res"},{"issue":"16","key":"2178_CR32","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1111\/jcmm.17832","volume":"27","author":"K Liu","year":"2023","unstructured":"Liu K, Zhang S, Gong Y, Zhu P, Shen W, Zhang Q. PSMC4 promotes prostate carcinoma progression by regulating the CBX3-EGFR-PI3K-AKT-mTOR pathway. J Cell Mol Med. 2023;27(16):2437\u201347. https:\/\/doi.org\/10.1111\/jcmm.17832.","journal-title":"J Cell Mol Med"},{"key":"2178_CR33","doi-asserted-by":"publisher","first-page":"116755","DOI":"10.1016\/j.bcp.2025.116755","volume":"233","author":"PK Roy","year":"2025","unstructured":"Roy PK, Deepak K, Das CK, et al. PSMC2 promotes resistance against temozolomide in glioblastoma via suppressing JNK-mediated autophagic cell death. Biochem Pharmacol. 2025;233:116755. https:\/\/doi.org\/10.1016\/j.bcp.2025.116755.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"2178_CR34","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jhep.2018.11.027","volume":"70","author":"Y Fan","year":"2019","unstructured":"Fan Y, Bazai SK, Daian F, et al. Evaluating the landscape of gene cooperativity with receptor tyrosine kinases in liver tumorigenesis using transposon-mediated mutagenesis. J Hepatol. 2019;70(3):470\u201382. https:\/\/doi.org\/10.1016\/j.jhep.2018.11.027.","journal-title":"J Hepatol"},{"key":"2178_CR35","doi-asserted-by":"publisher","first-page":"100663","DOI":"10.1016\/j.drup.2019.100663","volume":"48","author":"S Narayanan","year":"2020","unstructured":"Narayanan S, Cai CY, Assaraf YG, et al. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resist Updat. 2020;48:100663. https:\/\/doi.org\/10.1016\/j.drup.2019.100663.","journal-title":"Drug Resist Updat"},{"key":"2178_CR36","doi-asserted-by":"publisher","first-page":"814155","DOI":"10.3389\/fimmu.2021.814155","volume":"12","author":"R Fasano","year":"2022","unstructured":"Fasano R, Malerba E, Prete M, et al. Impact of Antigen Presentation Mechanisms on Immune Response in Autoimmune Hepatitis. Front Immunol. 2022;12:814155. https:\/\/doi.org\/10.3389\/fimmu.2021.814155.","journal-title":"Front Immunol"},{"key":"2178_CR37","doi-asserted-by":"publisher","first-page":"747","DOI":"10.2147\/PGPM.S418533","volume":"16","author":"W Huang","year":"2023","unstructured":"Huang W, Qian Z, Shi Y, et al. PSMC2 is a Novel Prognostic Biomarker and Predicts Immunotherapeutic Responses: From Pancreatic Cancer to Pan-Cancer. Pharmgenomics Pers Med. 2023;16:747\u201358. https:\/\/doi.org\/10.2147\/PGPM.S418533.","journal-title":"Pharmgenomics Pers Med"},{"key":"2178_CR38","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/CMAR.S449488","volume":"16","author":"L Feng","year":"2024","unstructured":"Feng L, Zhang N, Luo L, et al. Investigation of the Proteasome 26S Subunit, ATPase Family Genes as Potential Prognostic Biomarkers and Therapeutic Targets for Hepatocellular Carcinoma. Cancer Manag Res. 2024;16:95\u2013111. https:\/\/doi.org\/10.2147\/CMAR.S449488.","journal-title":"Cancer Manag Res"},{"issue":"21","key":"2178_CR39","doi-asserted-by":"publisher","first-page":"e2309348","DOI":"10.1002\/advs.202309348","volume":"11","author":"J Li","year":"2024","unstructured":"Li J, Zhang L, Xing H, et al. The Absence of Intra-Tumoral Tertiary Lymphoid Structures is Associated with a Worse Prognosis and mTOR Signaling Activation in Hepatocellular Carcinoma with Liver Transplantation: A Multicenter Retrospective Study. Adv Sci (Weinh). 2024;11(21):e2309348. https:\/\/doi.org\/10.1002\/advs.202309348.","journal-title":"Adv Sci (Weinh)"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02178-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02178-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02178-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:42:50Z","timestamp":1784248970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02178-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,24]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2178"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02178-4","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,24]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study involving human samples was approved by The Ethics Committee of The Second Affiliated Hospital of Soochow University (Approval No. JD-LK2024047). The component of this study involving human samples complies with the ethical principles of the Declaration of Helsinki. All animal experiments were approved by The Animal Experimentation Ethics Committee of Soochow University (approval No. 202406A0101). The animal study followed the ARRIVE guidelines and the ARRIVE Checklist is available [\n                      \n                      ].","order":2,"name":"Ethics","label":"Ethical statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"273"}}